First-In-Class Small Molecule Modulator of Neutrophil Trafficking and Activation

Preclinical

IND Enabling

Phase 1

Phase 2

Phase 3

ADS051

Ulcerative Colitis

ADS051 is an oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis. ADS051 blocks MRP2-mediated neutrophil trafficking into and FPR1-mediated neutrophil activation within the colonic lumen. Unlike currently available therapies, this addresses neutrophil-mediated tissue damage, a hallmark of UC pathology. In a healthy volunteer study and MAD patient study, ADS051 was safe and well tolerated and restricted to the gut with limited systemic exposure.

Publications

Featured Poster

ADS051, AN ORAL, GUT-RESTRICTED, SMALL MOLECULE NEUTROPHIL MODULATOR IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS RECEIVING MULTIPLE ASCENDING DOSES